Terns Announces Pricing of $75 Million Public Offering
December 20, 2022 19:40 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2022 08:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Announces Proposed Public Offering
December 19, 2022 16:31 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit
December 01, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 09, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at...
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
November 04, 2022 08:05 ET
|
Terns Pharmaceuticals, Inc.
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial...
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
October 26, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Announces $65 Million Oversubscribed Offering
August 12, 2022 08:00 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...